SIRT4 downregulation has been observed in multiple cancer types, and this deficit in CRC is associated with poor prognoses, lower survival rates, and reduced chemosensitivity [31,32,33,34,35]. This evidence concerns the gene SIRT4 and colorectal carcinoma.